<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129285</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-15366-1</org_study_id>
    <secondary_id>R01DA015366</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <secondary_id>704450</secondary_id>
    <nct_id>NCT00129285</nct_id>
  </id_info>
  <brief_title>Modafinil Treatment for Cocaine-Dependent Individuals</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Modafinil for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite years of active research, there are still no approved medications for the treatment
      of cocaine dependence. The purpose of this study is to determine the effectiveness of
      modafinil in treating cocaine-dependent individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modafinil is a glutamate-enhancing agent that blunts cocaine euphoria under controlled
      conditions. Due to its stimulant-like properties, modafinil is also likely to relieve severe
      cocaine withdrawal symptoms. In turn, this may lead to better clinical outcomes. The purpose
      of this study is to determine whether modafinil improves abstinence during early recovery
      from cocaine dependence.

      This 6-month, double-blind, placebo-controlled trial will enroll 210 participants with
      current DSM-IV diagnoses of cocaine dependence. Treatment will occur for 8 weeks.
      Participants will be randomly assigned to receive a single morning dose of low-dose modafinil
      (200 mg/day), high-dose modafinil (400 mg/day), or matching placebo tablets. In addition,
      each week participants will receive manual-guided cognitive behavioral therapy at the
      Treatment Research Center. At the end of the 8-week treatment period, modafinil or placebo
      will be abruptly discontinued. One week following, an end of medication evaluation will
      occur. In addition to this, two follow-up evaluations will take place 3 and 5 months after
      initial randomization. Efforts will be made to continue evaluation of subjects who decide to
      discontinue the modafinil treatment. Urine benzoylecgonine levels will be used to measure
      cocaine abstinence. Craving, withdrawal, retention, and adverse events will also be
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Toxicology for Cocaine</measure>
    <time_frame>3 weeks</time_frame>
    <description>Abstinent in the final 3 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention; Number of Evaluation Visits Attended</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of visits attended compared between the three conditions using anova</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine Selective Severity Assessment (CSSA) Total Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cocaine Selective Severity assessment (CSSA) total score has a range 0-126. Higher scores indicating greater severity of cocaine withdrawal obtained weekly. Groups compared using GEE model over 8 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Low Dose Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Modafinil 200 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose modafinil 400 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Modafinil</intervention_name>
    <description>modafinil 200 mg/day</description>
    <arm_group_label>Low Dose Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Modafinil</intervention_name>
    <description>modafinil 400 mg/day</description>
    <arm_group_label>High Dose Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 400 mg/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 - 60 years;

          -  Current DSM-IV diagnosis of cocaine dependence

          -  Using at least $200 worth of cocaine within the past 30 days and having positive urine
             toxicology (BE) during screening;

          -  Able to provide written informed consent and to comply with all study procedures;

          -  Women must be surgically sterile, at least two years postmenopausal, or if of
             childbearing potential be using a medically accepted method of birth control and agree
             to continue use of this method for at least 30 days after the last dose of study drug
             (i.e. barrier method with spermicide, steroidal contraceptive [oral and implanted,
             including Depo-Provera contraceptives must be used in conjunction with a barrier
             method], or intrauterine device [IUD])

        Exclusion Criteria:

          -  Currently dependent on any substance other than cocaine or nicotine

          -  Neurological or psychiatric disorders, such as psychosis, bipolar illness, organic
             brain disease, dementia, or any diseases that require psychotropic medications

          -  Serious medical illnesses, including but not limited to; uncontrolled hypertension,
             significant heart disease (including a history of myocardial infarction, angina,
             mitral valve prolapse, left ventricular hypertrophy, palpitations, and arrhythmia),
             hepatic disease, renal disease, or any serious, potentially life-threatening or
             progressive medical illness that may compromise patient safety or study conduct;

          -  Received a drug with known potential for toxicity to a major organ system within the
             month prior to entering treatment including but not limited to; chemotherapeutic
             agents for neoplastic disease (i.e. methotrexate, vincristine, vinblastine,
             fluorouracil), agents used for parasitic infections, isoniazid, chlorambucil,
             dactinomycin, chloramphenicol, immunosuppressive and cytotoxic agents (i.e.
             cyclosporine, tacrolimus), indomethacin, protease inhibitors, amphotericin B,
             cephalosporins, aminoglycosides, interferon, and sulfonamides;

          -  Clinically significant abnormal laboratory values

          -  Has any disease of the gastrointestinal system, liver, or kidneys which could result
             in altered metabolism or excretion of the study medication (history of major
             gastrointestinal tract surgery, gastrectomy, gastrostomy, bowel resection, etc.) or
             history of chronic gastrointestinal disorders (ulcerative colitis, regional enteritis,
             or gastrointestinal bleeding);

          -  Known hypersensitivity or allergy to modafinil or receiving chronic therapy with any
             medication that could interact adversely with one of the medications under study,
             including propranolol, phenytoin, warfarin and diazepam;

          -  Currently taking any medication that could interact adversely with one of the
             medications under study, including propranolol, phenytoin, warfarin and diazepam

          -  Took monoamine oxidase inhibitors (MAOI) within 30 days prior to randomization;

          -  Taking or has taken an investigational drug within 60 days prior to enrollment

          -  If female and of child-bearing capacity, tests positive on a urine pregnancy test, is
             lactating, has had three or more days of amenorrhea beyond expected menses at the time
             of the first dose of study medication, is contemplating pregnancy in the next 6
             months, or is not using an effective contraceptive method;

          -  Received therapy with any opiate-substitute (methadone, LAAM, buprenorphine) within 60
             days of study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Dackis</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 6178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/csa/trc_clinical_trials.html</url>
    <description>Click here for more information about the University of Pennsylvania Treatment Research Center's current studies</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <results_first_submitted>March 27, 2017</results_first_submitted>
  <results_first_submitted_qc>April 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2018</results_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Modafinil</title>
          <description>Low Dose Modafinil
Modafinil Low Dose: participants received modafinil 200 mg/day</description>
        </group>
        <group group_id="P2">
          <title>High Dose Modafinil</title>
          <description>High Dose Modafinil
Modafinil High Dose: participants received modafinil 400 mg/day</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
Placebo: participants received placebo 400 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Modafinil</title>
          <description>Low Dose Modafinil
Modafinil Low Dose: modafinil 200 mg/day</description>
        </group>
        <group group_id="B2">
          <title>High Dose Modafinil</title>
          <description>High Dose Modafinil
Modafinil High Dose: modafinil 400 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo
Placebo: placebo 400 mg/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.72" spread="6.9"/>
                    <measurement group_id="B2" value="43.64" spread="7.7"/>
                    <measurement group_id="B3" value="42.46" spread="7.5"/>
                    <measurement group_id="B4" value="42.64" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urine Toxicology for Cocaine</title>
        <description>Abstinent in the final 3 weeks of treatment</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Modafinil</title>
            <description>Low Dose Modafinil
Modafinil Low Dose: participants received modafinil 200 mg/day</description>
          </group>
          <group group_id="O2">
            <title>High Dose Modafinil</title>
            <description>High Dose Modafinil
Modafinil High Dose: participants received modafinil 400 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: participants received placebo 400 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Toxicology for Cocaine</title>
          <description>Abstinent in the final 3 weeks of treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention; Number of Evaluation Visits Attended</title>
        <description>Number of visits attended compared between the three conditions using anova</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1Low Dose Modafinil</title>
            <description>Low Dose Modafinil 200 mg daily
Modafinil Low Dose: modafinil 200 mg/day</description>
          </group>
          <group group_id="O2">
            <title>2 High Dose Modafinil</title>
            <description>High Dose Modafinil 400 mg daily
Modafinil High Dose: modafinil 400 mg/day</description>
          </group>
          <group group_id="O3">
            <title>3. Placebo</title>
            <description>Placebo
Placebo: placebo 400 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Retention; Number of Evaluation Visits Attended</title>
          <description>Number of visits attended compared between the three conditions using anova</description>
          <units>number of evaluation sessions attended</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="7.1"/>
                    <measurement group_id="O2" value="16.5" spread="6.7"/>
                    <measurement group_id="O3" value="14.3" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Selective Severity Assessment (CSSA) Total Score</title>
        <description>Cocaine Selective Severity assessment (CSSA) total score has a range 0-126. Higher scores indicating greater severity of cocaine withdrawal obtained weekly. Groups compared using GEE model over 8 weeks of treatment.</description>
        <time_frame>8 weeks</time_frame>
        <population>patients exposed to low dose and high dose modafinil</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Modafinil</title>
            <description>Low Dose Modafinil
Modafinil Low Dose: participants received modafinil 200 mg/day</description>
          </group>
          <group group_id="O2">
            <title>High Dose Modafinil</title>
            <description>High Dose Modafinil
Modafinil High Dose: participants received modafinil 400 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Selective Severity Assessment (CSSA) Total Score</title>
          <description>Cocaine Selective Severity assessment (CSSA) total score has a range 0-126. Higher scores indicating greater severity of cocaine withdrawal obtained weekly. Groups compared using GEE model over 8 weeks of treatment.</description>
          <population>patients exposed to low dose and high dose modafinil</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.89" spread="11.70"/>
                    <measurement group_id="O2" value="15.04" spread="13.52"/>
                    <measurement group_id="O3" value="15.2" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the course of the 8 week trial</time_frame>
      <desc>Adverse events for low and high dose modafinil were combined and compared to adverse events occurring in the placebo comparator group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Modafinil High Dose</title>
          <description>Modafinil 400 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo daily</description>
        </group>
        <group group_id="E3">
          <title>Modafinil Low Dose</title>
          <description>modafinil 200 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Treatment Emergent Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>appetite changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Stomach problems</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>teeth problems</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Body Aches</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased energy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kyle Kampman</name_or_title>
      <organization>University of Pennsylvania Treatment Research Center</organization>
      <phone>215-746-2764</phone>
      <email>kampman@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

